<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03534674</url>
  </required_header>
  <id_info>
    <org_study_id>H17-03264</org_study_id>
    <nct_id>NCT03534674</nct_id>
  </id_info>
  <brief_title>Vitamin D3 Supplementation for AlloHSCT-RCT</brief_title>
  <official_title>Validating a Vitamin D3 Supplementation Regimen Among Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess whether a single oral loading dose of 100,000 IU vitamin D3 prior to
      allogeneic hematopoietic stem cell transplant (aHSCT) can achieve optimal 25 hydroxy-vitamin
      D3(25-OH-D3) levels (&gt;75nmol/L) at one month post aHSCT, and maintain adequate levels for at
      least three months, compared to our standard practice of 2000 IU vitamin D3 daily. 25-OH-D3
      levels will be measured prior to vitamin D3 supplementation, and 30 as well as 100 days post
      vitamin D supplementation. We hypothesize that the intervention will prevent vitamin D
      insufficiency or deficiency in aHSCT recipients, therefore benefit aHSCT-associated
      morbidity, including osteoporosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized non-blinded single centre prospective clinical trial designed to
      validate whether a single oral loading dose of 100,000 IU vitamin D3 prior to allogeneic
      hematopoietic stem cell transplant (aHSCT) can achieve optimal 25 hydroxy-vitamin
      D3(25-OH-D3) levels (&gt;75nmol/L) at one month post aHSCT, and maintain adequate levels for at
      least three months, compared to our standard practice of 2000 IU vitamin D3 daily.

      84 patients will be enrolled. Following completion of all baseline data collection,
      participants will be randomized 1:1 to the intervention group or the control group on the
      admission day for aHSCT

      Patients in the intervention group will receive a single oral loading dose of 100,000 IU
      vitamin D3, with subsequent vitamin D3 2000 IU daily. Patients assigned to the control group
      will receive our current standard of care, 2000 IU vitamin D3 daily.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2018</start_date>
  <completion_date type="Anticipated">December 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of 100,000 IU vitamin D3 prior to aHSCT</measure>
    <time_frame>1 year</time_frame>
    <description>To assess the efficacy (the proportion of patients achieving sufficient serum 25-OH-D3 level) after a single oral loading dose of 100,000 IU vitamin D3 prior to aHSCT, with subsequent vitamin D3 2000 IU daily, in preventing vitamin D insufficiency/deficiency in the first 100 days post-aHSCT.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to the intervention group will receive a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, with subsequent vitamin D3 2000 IU daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants assigned to the control group will be advised to take our current vitamin D regimen (2000 IU vitamin D3 daily).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin D3</intervention_name>
    <description>a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, then 2000 IU vitamin D3 daily.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients undergoing allogeneic stem cell transplantation at the Leukemia/BMT Program
             of British Columbia.

          2. Age greater than or equal to 18 years.

          3. Able to provide written informed consent.

        Exclusion Criteria:

          1. Hypercalcemia, hypervitaminosis D, or allergic/ sensitive to vitamin D.

          2. Not meeting eligibility criteria to proceed with allogeneic stem cell transplantation
             as per the Leukemia/BMT Program of BC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raewyn Broady, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicola Bai</last_name>
    <phone>604-875-4111</phone>
    <phone_ext>69013</phone_ext>
    <email>nicola.bai@bccancer.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raewyn Broady, MBChB</last_name>
    <phone>604-875-4863</phone>
    <email>RBroady@bccancer.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2018</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Raewyn Broady</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

